MeiraGTx initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of MeiraGTx (MGTX) with a Buy rating and $20 price target The firm has conviction that AAV-AQP1 for radiation-induced xerostomia is one of the most “risk-mitigated late-stage gene therapy programs in development.” It recommends buying the shares ahead of the pivotal data in late 2026 or early 2027.